Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Recruiting 133Completed 97Unknown 75Terminated 41Active not recruiting 28Not yet recruiting 24Withdrawn 5Suspended 2Enrolling by invitation 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Breast Neoplasms 369Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 140Colorectal Neoplasms 137Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 122Lymphoma 114Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 88Head and Neck Neoplasms 88Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 61Hematologic Neoplasms 59Sarcoma 55Glioma 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Advanced Solid Tumor × Clear all
NCT06219499 2024-04-03

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

OncoC4, Inc.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT05791474 2023-11-29

ATI-2231 in Advanced Solid Tumor Malignancies

Washington University School of Medicine

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT05381935 2023-01-31

A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Elpiscience Biopharma, Ltd.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT04797468 2023-01-17

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Shanghai Henlius Biotech

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT04878484 2022-09-02

Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Athenex, Inc.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡